Merck wins first FDA approval for Keytruda as a treatment for mesothelioma
Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a ...
Merck Gets European Panel Backing for Keytruda in Two Gynecologic Cancers
Merck & Co. said a European Medicines Agency panel recommended expanded approval of the drugmaker's blockbuster cancer treatment Keytruda in two types of gynecologic cancers.
Seeking Alpha on MSN2d
Merck’s Keytruda label expanded in the U.S. for mesothelioma
Merck (NYSE:MRK) announced Wednesday that the U.S. Food and Drug Administration (FDA) approved a label expansion for its ...
Merck and Siemens Enter Strategic Partnership on Digital Transformation Technology
Merck, a leading science and technology company, and Siemens deepened their cooperation aimed at taking smart manufacturing ...
Behind the Scenes of Merck & Co's Latest Options Trends
Deep-pocketed investors have adopted a bullish approach towards Merck & Co MRK, and it's something market players shouldn't ...
Business Insider3d
Daiichi Sankyo, Merck's Patritumab Deruxtecan Meets Primary Goal In HERTHENA-Lung02 Phase 3 Study
(RTTNews) - Merck & Co Inc. (MRK) on Tuesday said HERTHENA-Lung02 phase 3 study evaluating Daiichi Sankyo and Merck's patritumab deruxtecan in patients with EGFR-mutated non-small cell lung cancer ...
Business Insider5d
Merck : KEYTRUDA Combination Cuts Death Risk By 34% In Late-Stage Breast Cancer Trial
(RTTNews) - Merck & Co Inc.'s (MRK) anti-PD-1 therapy, KEYTRUDA (pembrolizumab), when combined with chemotherapy before surgery and continued as a single agent after surgery, reduced the risk of ...
Seeking Alpha1d
Merck & Co., Inc. (MRK) Bank of America Global Healthcare Conference (Transcript)
Thank you for attending our Global Healthcare Conference. Today, I have the pleasure to host Joe Romanelli, President of Human Health International; and Peter Dannenbaum, Head of Investor Relations.
Yahoo Finance7d
Here's Why Merck (MRK) Gained But Lagged the Market Today
In the latest market close, Merck (MRK) reached $115.25, with a +0.47% movement compared to the previous day. This change lagged the S&P 500's 0.75% gain on the day. Meanwhile, the Dow gained 0.58 ...
Yahoo2d
Daiichi Sankyo-Merck's 'guided-missile' cancer drug meets main goal in late-stage trial
(Reuters) -Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some patients with a form of lung cancer lived without their ...
STAT3d
FDA formalizes protocol for international cancer trials
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. I’m in New York this week with my colleague Adam ...
The Globe and Mail6d
Where Will Merck Stock Be in 5 Years?
Merck(NYSE: MRK) stock has been a longtime winner for investors, returning 72% in the past five years. A major factor in this pharmaceutical giant's success is its Keytruda immunotherapy drug ...